BACKGROUND: Primary @entity96 with hepatocellular and cholangiocellular differentiation (b[HB]-PLC) are rare. Surgery offers the best prognosis, but there is a paucity of literature to guide therapy for @entity1 with advanced or unresectable disease. This study aimed to evaluate outcomes of hepatic-directed therapy compared with those of systemic chemotherapy and surgery. METHODS: A retrospective evaluation of @entity1 with b(HB)-PLC from 1 January 2008 to 1 September 2014 was conducted. The @entity1 were divided into the following four groups: transplantation (TX) group, surgical resection (SX) group, @entity99 ( @entity99 ) group, and systemic chemotherapy alone (SC) group. Overall and progression-free survival, treatment response, and clinicopathologic data were analyzed. RESULTS: The study included 79 @entity1 (37 females) with an average age of 62  years. The number of @entity1 in each group were as follows: TX group (n  =  6), SX group (n  =  27), @entity99 group (n  =  18), and SC group (n  =  28). The mean follow-up periods were 33  months for the TX group, 17  months for the SX group, 14  months for the @entity99 group, and 7  months for the SX group. Overall, 28  % of the @entity1 had @entity82 and 35  % had @entity99 . The candidates for surgery comprised 42  % of the @entity1 . The @entity99 group (n  =  18) had a significantly greater objective response than the SC group (n  =  28) (47 vs. 6  %; p  =  0.02). Two @entity1 who underwent hepatic arterial infusion pump treatment were downstaged to resection. A trend toward improved OS/PFS was observed in the @entity99 group versus the SC group, although statistically significant. The SX group had significantly improved survival (p  <  0.001) as did the transplanted @entity1 . CONCLUSIONS: Although surgery offers the best survival for b(HB)-PLC @entity1 , only a minority are candidates for surgery. Because @entity99 therapy showed a superior objective response over SC therapy, it may offer a survival advantage and may downstage @entity1 for surgical resection or transplantation.

Biphenotypic Primary XXXX : Assessing Outcomes of Hepatic Directed Therapy.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity82 :: ('MESH:D005355', 'Disease') :: ['cirrhosis'] @entity99 :: ('MESH:D056486', 'Disease') :: ['hepatic directed', 'HD', 'viral hepatitis'] @entity96 :: ('MESH:D008113', 'Disease') :: ['liver carcinomas']
@entity96 :: (MESH:D008113,Disease) :: ['Liver Carcinomas']
